microbiome company News
-
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 ...
By BiomX
-
Microviable Therapeutics is hiring!
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit your credentials: Microviable careers ...
-
BiomX Announces Publication in the Journal, Bioinformatics
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. ...
By BiomX
-
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX005 in atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (“RAD”) 2021 Virtual Conference and will ...
By BiomX
-
BiomX Announces Corporate Restructuring
Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the third quarter of 2022 and readout from part 2 of the study expected in the first quarter of 2023 Atopic Dermatitis Program will be delayed due to restructuring BiomX Inc. (NYSE ...
By BiomX
-
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients CF Foundation to Invest up to $5 Million in BiomX Common Stock Data Readouts from Phase 1b/2a CF Trial of BX004 Expected in 2022 BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel ...
By BiomX
-
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license ...
By BiomX
-
MV Biotherapeutics and Malcisbo agree to explore the Apyrase technology platform for AH Vaccines
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
-
20th Annual Biotech in Europe Forum for global partnering & investments
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners. Please contact us for a personal meeting within the partnering system or outside it. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in ...
-
Bio International Convention Digital June 8-12, 2020
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) . We look forward meeting potential investors and licensing partners. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome ...
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis for licensure application to ...
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
-
Intus Bio Announces New Canadian Distribution Partnership with D-Mark Biosciences to Accelerate Microbiome Research
Intus Biosciences, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into a distribution partnership for the promotion, sale and support of all Intus Biosciences products and software in Canada. “Canada is experiencing significant growth in microbiome research,” said Duane Mendis, General ...
-
New company name and website
We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV). “During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original ...
-
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
AOBiome Therapeutics ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the election of Jun Wang, Ph.D., founder and CEO of iCarbonX, as Chairman of AOBiome's Board of Directors, effective May 31, 2018. Dr. Wang has served on ...
-
Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet’s Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden. Dr. Blount joins two colleagues from Ferring Pharmaceuticals currently serving on the JSC – Per Falk, M.D., ...
-
Atmo Biosciences secures $9.6 million in oversubscribed capital raise
Atmo Biosciences has closed a successful, oversubscribed A$9.6m capital raise. The raise was led by two new, cornerstone investors – Sydney-based investment firm Alium Capital Management and Japanese multinational company Otsuka Pharmaceutical. The funding will enable Atmo to accelerate product development of its gas-sensing capsule, which detects clinically important gaseous biomarkers ...
-
AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
-
Intus Bio Announces New Distribution Partnership with BioCat GmbH to Accelerate Microbiome Research in Germany, Austria and Switzerland
Intus Bios, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into an exclusive distribution partnership with BioCat GmbH, a leading provider of life sciences solutions, for the promotion, sale and support of all Intus Biosciences products and software in Germany, Austria, and Switzerland. Founded in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you